

Clinical Practice Guideline for Care Around Stillbirth and Neonatal Death

Version 3.1, March 2018

Endorsed by



SECTION 5

INVESTIGATIONS FOR STILLBIRTH

5.1 Introduction

This section of the PSANZ Clinical Practice Guideline for Care Around Stillbirth and Neonatal Death presents recommended investigations to be undertaken following fetal death/stillbirth. Accurate identification of the cause of stillbirth is the cornerstone to prevention and is critically important to parents to help them to understand why their baby has died and to plan future pregnancies. The high proportion of unexplained stillbirths reported globally is an impediment to these goals¹. Wide variation in reported causes of stillbirth internationally has been attributed to different approaches to investigation. However, the classification system used also plays a role². Please refer to Section 7 of the PSANZ Clinical Practice Guideline for Care Around Stillbirth and Neonatal Death for further details on classification of stillbirths and neonatal deaths.

This update of the guideline has been undertaken through a partnership between PSANZ and the NHMRC Stillbirth Centre of Research Excellence in Stillbirth.

In this section of the PSANZ Guideline for Care Around Stillbirth and Neonatal Death, for practice recommendations to assist clinicians to implement the guideline recommendations see *Appendices A - T*.

5.2 Objective of this section

The objective of this section is to provide guidance on the investigations to perform following a stillbirth to identify an accurate cause of death. Detailed objectives are:

- To provide quality information for parents to help understand why the death occurred;
- To inform future pregnancy planning;
- To inform care in future pregnancies; and
- To inform strategies for prevention at the population-level, and future research.

5.3 What has changed in this update?

The findings of a recent literature review have informed changes in this update. Readability has also been enhanced and reduced duplication across the different sections of the guidelines.

Several investigations previously recommended as core investigations following all stillbirths are now recommended as selective investigations only. These investigations (e.g. thrombophilia studies, tests for infectious diseases, Haemoglobin A1c (HbA1c), liver function and bile acid tests) should be undertaken on the basis of the results of core investigations. Maternal ultrasound scan, full blood count, renal and thyroid function testing are no longer recommended investigations for determining the causes of stillbirth. Amniocentesis for cytogenetic analyses and microbiological studies are no longer recommended.

5.4 Research gaps

Due to the lack of high-quality studies on appropriate diagnostic testing following stillbirth, contentious issues remain and, consequently, components of stillbirth investigation protocols internationally vary^{3,4}. While there are limited data on costs of stillbirth investigations, one study from the US by Michalski et al in 2002 suggest that a specific comprehensive investigation

protocol was of sufficient economic value to be incorporated into routine antenatal care⁵. Others report that a selective⁶ or sequential approach to testing may be appropriate^{7,8}. The findings of the National Health and Medical Research Council (NHMRC)-funded study on the yield and costs and benefits of stillbirth investigations across maternity settings in Australia and a Cochrane systematic review of the evidence for test protocols⁴ are expected in 2017 and 2018.

5.5 Approach to investigation of stillbirth

The recommended investigations following stillbirth include those that should be routine for the majority of stillbirths (core investigations) and those that should be carried out based on information revealed from core investigations, or in the presence of specific clinical scenarios (sequential or selective investigations) (see Figure 1).

Situations will exist where the cause of a fetal death is already known (e.g. unequivocal diagnosis from prenatal testing), however, as selective investigative approaches may result in important diagnoses being missed⁹, a non-selective approach using the core investigations should be the standard in the absence of unequivocal diagnosis from prenatal testing. The relative merits of not following this approach should be considered on an individual-case basis and involve consultation with the family. Depending on the particular circumstances of a perinatal death (e.g. family wishes, access to services), it may not be feasible for some stillbirth investigations to be carried out.


This Guideline provides checklists and data collection forms (*see Appendix A – T*) to assist clinicians with uniform investigation and reporting of stillbirths.

Section 5 Recommendations for stillbirth investigations

- 1** A non-selective approach according to the recommended core investigations should be adopted for all stillbirths (unless the cause of death has been unequivocally determined antenatally). These investigations are:
 - Comprehensive maternal (medical, social, family) and pregnancy history
 - Kleihauer-Betke test/Flow cytometry for fetal to maternal haemorrhage
 - External examination of the baby performed by the attending clinician
 - Clinical photographs of the baby
 - Autopsy
 - Detailed macroscopic examination of the placenta and cord
 - Placental histopathology
 - Cytogenetics (Chromosomal microarray (CMA) or karyotype if CMA is not available).
- 2** Further sequential and/or selective investigations should be undertaken according to the particular clinical scenario based on a comprehensive history, and information gained from core investigations.
- 3** An external examination of the baby should be performed at birth by the attending clinician using the recommended checklist (*Please refer to Appendix D – Clinical examination of baby checklist*) and clearly documented in the medical record. Where the family has consented to autopsy, all information gained from the initial external

examination (along with comprehensive maternal (medical, social, family) and pregnancy history) should be forwarded to the pathology service to guide this procedure.

- 4** Following a stillbirth, the placenta, membranes and cord should be kept refrigerated and, where feasible, sent fresh and unfixed for macroscopic and histological examination by a perinatal pathologist. The pathology service should be informed if the parents have requested return of the placenta following examination.
 - 5** Clinicians should discuss the value of a full autopsy with parents in all cases of perinatal death where the cause of death is not already known. If the parents decline a full autopsy, a limited/partial autopsy should be offered.
-



APS: Antiphospholipid syndrome; CMA: Chromosomal microarray; CMV: Cytomegalovirus; FGR: Fetal growth restriction; LFTs: Liver Function Tests; LGA: Large-for gestational-age; HbA1c: Haemoglobin A1c; MIA: Minimally-invasive autopsy; MRI: Magnetic Resonance Imaging; NIA: Non-invasive autopsy; SGA: Small for gestational age.

Figure 1: Stillbirth investigations algorithm

5.6 Core investigations for all stillbirths

After the diagnosis of stillbirth, and at an appropriate time, the responsible clinician should explain to the parents the value of performing the recommended core investigations as outlined below.

Maternal history

A comprehensive maternal (medical, social, family) and pregnancy history should be taken following all perinatal deaths.

Please refer to *Appendix E – Australian perinatal mortality audit tool*; and *Appendix G – New Zealand Rapid reporting form for a perinatal death - mother*

Fetal-maternal haemorrhage (FMH)

In a large study from Ireland over 25 years, fetal-maternal haemorrhage (FMH) accounted for 4.1% of antepartum stillbirths, mostly at term gestations (74%), with multiple gestations being up to six times as likely to be affected as singleton pregnancies¹⁰. Another case controlled study also noted that women with FMH were more likely to work outside the home during pregnancy than women without evidence of FMH¹¹. By general consensus, >50ml is considered a significant fetal haemorrhage, although various studies use limits ranging from 30 to 150ml^{12,13}. However, as the impact of a haemorrhage of a given volume is dependent on gestational age, fetal size and total blood volume, individual assessments need to be calculated¹⁴.

A Kleihauer-Betke test or flow cytometry to detect FMH should be performed following the diagnosis of any fetal death, preferably prior to birth^{7,15-18}. Limited evidence suggests that this may also be useful postpartum^{18,19}.

Please refer to Appendix B – Estimation of severity of feto-maternal haemorrhage.

Autopsy

Please refer to *Section 4 Perinatal autopsy examination for further details on the post-mortem examination* and *Section 3 Psychological and social aspects of perinatal bereavement, Appendix M – Infant autopsy consent brochure* and *Appendix N – Information for health professionals seeking consent* for information brochures for parents and professionals about post-mortem examinations.

The following should accompany the infant for autopsy examination:

- Autopsy consent form
- Placenta (fresh and unfixated)
- Comprehensive maternal (medical, social, family) and pregnancy history
- Copies of the death certificate
- Copies of all antenatal ultrasound reports (including post-mortem ultrasound if undertaken)
- Copy of prenatal karyotyping results if available
- Findings from initial external examination performed at birth by attending clinician using the checklist provided (*Please refer to Appendix D – Clinical examination of baby checklist*).

External examination of the baby

A comprehensive external examination of the baby is an essential component of the investigation of a stillbirth^{15,20-28}. A report on a large case series from the Wisconsin Stillbirth Service Program (WiSSP) suggested that approximately 25% of stillborn infants were found, on clinical examination, to have demonstrable abnormalities and also indicated that lack of external examination would have resulted in approximately 4% of diagnoses being missed²⁹.

A detailed external examination of the baby is a component of a full autopsy. As the perinatal pathologist is the most appropriate person to carry out the external examination, parents who have declined a full autopsy should be asked for their consent for the baby to have a detailed external examination by a perinatal pathologist. This should not replace the initial external examination performed at birth by the attending clinician, which may provide important information to guide the full autopsy. In the circumstance where it is not possible for a pathologist to perform the examination, then a neonatologist or paediatrician or clinical geneticist should conduct the examination. A proforma is provided to assist the midwife/doctor in carrying out the procedure.

Please refer to Appendix D – Clinical examination of baby checklist.

Clinical photographs

Clinical photographs should be taken for every stillborn baby for later review. The clinical photographs are additional to the bereavement photographs, and should be clearly labelled and filed in the medical record. The WiSSP case series indicates that 28% of all stillborn babies had observable abnormalities identifiable on photographs and photographs were critical in establishing a diagnosis in approximately 5% of cases²⁹. Consent from the parents for clinical photographs should be documented in the medical record.

Please refer to Appendix H – Instructions on taking clinical photographs

Placental and cord investigations by clinician

At time of birth, the clinician should undertake:

- A detailed macroscopic examination of the placenta and cord and document the normal and abnormal findings;
- Sampling of cord and placental tissue for chromosomal analysis (only if the placenta is not being sent to the pathology service). If a prenatal karyotype has already been performed, these samples should still be taken for DNA extraction and storage;
- Following a stillbirth, the placenta, membranes and cord should be sent fresh and unfixed for macroscopic and histological examination. If removal of an entangled cord from the baby is necessary, then clinical photographs should be taken first.

Please refer to Appendix C – Placental examination; Accoucheur flow chart.

Placenta, membranes and cord histopathology

Examination of the placenta, membranes and cord should occur for all stillbirths. The placenta, membrane and cord should be sent to the pathologist fresh and unfixed for histopathological examination once samples have been collected for cytogenetics and microbiology. A perinatal/paediatric pathologist should undertake the examination³⁰. For further details, please

refer to Section 4. A standardised reporting form for placental histopathology is provided to enable high quality reporting (See *Appendix P – Placental histopathology reporting form*).

Cytogenetic investigations

Chromosome microarray (CMA), in contrast to conventional culture karyotyping, uses DNA and does not require viable cells, which means that chromosomal abnormalities can be detected in macerated stillbirth samples³¹⁻³³. Microarray is also superior to karyotype as it can detect additional genetic abnormalities, including microdeletions and microduplications³². Targeted genetic testing using fetal and/or placental DNA (e.g. for monogenic disorders) will always have a place where a specific phenotype is suspected or when the family history is informative.

Advances in molecular genetic testing using DNA have facilitated a greater depth of testing of both the fetal and placental genome. New technologies currently under evaluation include exome and whole genome sequencing³⁴. Such advances have highlighted the importance of storing fetal and placental DNA for later evaluation where a cause for fetal death remains unknown.

Specific advice around extended genetic investigation cannot be prescribed at this time as data are limited, and access is variable and costs are generally high. It is therefore recommended that each service explore genetic testing options available to them both locally and further afield through transportation of tissue or DNA samples.

5.7 Selective investigations based on findings of core investigations

Congenital infections

Routine testing of all stillbirths for infection is no longer recommended^{7,18}. Targeted investigation should be undertaken if infection is suspected on the basis of maternal history, autopsy and/or placental findings¹⁸ and/or a small for gestational age (SGA) baby. To assign infection as the cause of death, positive serology should be supported by autopsy and/or placental findings consistent with infection^{17,18}. Detailed information about specific infections is outlined below.

Cytomegalovirus (CMV)

Cytomegalovirus is the most frequent infectious cause of newborn developmental abnormalities in the developed world³⁵. A prospective study of more than 10,000 women found an increase in fetal loss associated with infection in early pregnancy³⁶. CMV DNA can be detected in a high proportion of fetal or placental tissue samples and a strong association between CMV infection in pregnancy and stillbirth is suggested³⁷. CMV can also infect the placenta and is associated with villitis³⁸. Congenital CMV may also be discovered in cases where there are no obvious macroscopic sequelae³⁹. Maternal CMV serology CMV should be considered where placental histopathology shows evidence of CMV infection and/or when the baby is SGA.

Toxoplasmosis

Congenital toxoplasmosis can cause miscarriage, stillbirth, neurological disability and visual impairment but the majority of fetuses infected will not have sequelae. As toxoplasmosis is not

a common cause of stillbirth⁴⁰, routine testing in the absence of other indications is not recommended.

Parvovirus (B19)

Parvovirus (B19) can cause severe fetal anaemia, nonimmune hydrops and fetal death^{40,41}. One study found parvovirus to be the cause of death in 10% of all non-malformed fetal deaths that occurred between 10 and 24 weeks of gestation and referred for pathological examination⁴². A small proportion of susceptible pregnant women (1%-3%) will develop serologic evidence of parvovirus infection in pregnancy, of which the transmission rate to the fetus is between 17% and 33%⁴³⁻⁴⁵. The spontaneous loss rate of fetuses affected by Parvovirus B19 after 20 weeks gestation is 2.3%^{44,46,47}. However, where parvovirus has caused stillbirth, signs of the disease will be evident following examination of the baby and/or placenta. Routine testing following stillbirth in the absence of other indications is therefore not recommended. Testing for parvovirus should be recommended where severe anaemia and/or non-immune hydrops is found^{7,18}.

Rubella

Rubella is associated with a wide variety of fetal abnormalities including stillbirth^{48,49}. However with universal vaccination, congenital rubella infection in developed countries is rare⁵⁰. Most pregnant women are immune and, if they have not been tested during the initial routine antenatal blood testing, testing for rubella should be done only if indicated on the basis of core investigations.

Syphilis

Congenital syphilis may result in fetal loss/neonatal death, prematurity and major long term sequelae in surviving children. In a South American study, even after controlling for congenital anomalies, gestational age, maternal age, and previous stillbirth, gestational syphilis was significantly associated with stillbirth (odds ratio 1.88, 95% confidence interval 1.25-2.83; P=0.002)⁵¹. This increase in mortality with congenital syphilis has also been confirmed in a systematic review on this topic⁵². Antenatal screening for syphilis for all women is currently recommended to facilitate treatment early in pregnancy. Syphilis remains an uncommon cause of stillbirth in developed settings¹⁸ and routine testing following stillbirth in the absence of other indications is not currently recommended.

Other investigations

Blood group and antibody screen

A maternal blood group and antibody screen is recommended as a routine antenatal test at booking and again in the 3rd trimester of pregnancy. If a blood group and antibody screen has not been performed antenatally, it should be performed selectively to exclude haemolytic disease of the fetus due to maternal sensitisation to red cell antigens⁵³ where the baby is anaemic, jaundiced and/or hydropic.

Thrombophilia testing

Inherited thrombophilia⁵⁴ has been associated with a number of adverse pregnancy outcomes including stillbirth, but the relationship remains controversial and the role of testing is still debated. The role of treatment for women with inherited thrombophilia and adverse pregnancy outcomes also remains controversial⁵⁵⁻⁵⁷.

The most common acquired thrombophilia is the antiphospholipid syndrome (APS). The diagnosis of APS includes venous or arterial thrombosis and/or fetal loss in the presence of antiphospholipid antibodies (anticardiolipin, lupus anticoagulant, anti-B2 glycoprotein-1). Confirmation of the presence of antiphospholipid antibodies is required at a minimum of 12 weeks apart, after an initial positive test. APS is associated with both early and late fetal loss, pre-eclampsia and placental insufficiency. The prevalence of antiphospholipid antibodies is estimated to be 5% while the syndrome affects 0.5%⁵⁸. In a systematic review, the presence of antiphospholipid antibodies was significantly associated with late fetal loss⁵⁹.

The presence of thrombophilia may be most significant where placental pathology is apparent¹⁸. In a small prospective cohort study, 64% of women who had a stillbirth of placental cause had at least one thrombophilia⁶⁰. This proportion was increased to 70% when looking specifically at preterm stillbirths of placental cause. A population based study in Finland found an almost four-fold increased risk of Factor V Leiden mutation among women with unexplained stillbirth⁶¹. The prevalence of this mutation was over ten-fold among women with an unexplained stillbirth in the presence of placental lesions. More recently, a population-based case-control study within the Stillbirth Collaborative Research Network found the only heritable thrombophilia associated with stillbirth was Factor V Leiden mutation, and the association was statistically weak⁵⁵.

Given the evidence, routine testing for thrombophilic disorders following stillbirth without other indications is not currently justified. Testing for APS (anticardiolipin, lupus anticoagulant, and anti-B2 glycoprotein-1 antibodies)^{60,62} is recommended selectively where stillbirth occurs in the presence of one or more of the following: (1) family history of thrombosis; (2) personal history of venous thrombosis; (3) fetal growth restriction; (4) placental abruption or (5) placental infarction^{8,54}. Other thrombophilia studies, such as Prothrombin G20210A mutation^{60,63-65} and Factor V Leiden mutation^{55,61,65}, should be carried out as indicated and in accordance with individual jurisdiction guidance.

Haemoglobin A1c (HbA1c)

Increased risk of fetal morbidity and mortality for women with pre-existing diabetes is well known. A stillbirth rate of 35 per 1000 births for Type 2 diabetic mothers has been reported⁶⁶, and a systematic review has shown that women with pre-existing diabetes have an almost three-fold increased risk of stillbirth⁶⁷. There is some evidence to indicate that gestational diabetes mellitus (GDM) is also associated with increased perinatal mortality⁶⁸, and poor detection and management of the condition has been documented in association with term antepartum stillbirth⁶⁹. It is recognised that some women with GDM have unrecognised type 2 diabetes, with unfavourable pregnancy outcomes⁷⁰. HbA1c provides information about maternal glycaemia over the previous 3 months by reflecting the average glucose concentration over the life of the red cells⁷¹. Therefore, it may provide information regarding the contribution of maternal diabetes to a fetal death. One study suggested that pregnant women with an HbA1c of $\geq 5.4\%$

(36 mmol/mol) may have gestational diabetes⁷². Another study also noted that although HbA1c cannot replace Oral Glucose Tolerance Test (OGTT) in the diagnosis of GDM, it can be used as a screening test if a cut-off of 5.3% is used⁷³. In such women an OGTT should be performed postnatally. Nonetheless, diabetes has not been shown to be a common cause of stillbirth⁷. Routine HbA1c following stillbirth without other indication is not currently justified^{7,18}. It is recommended that HbA1c be carried out where SGA, FGR or SGA is detected. Please refer to the Australian Diabetes in Pregnancy Society Guidelines or the New Zealand Screening, Diagnosis and Management of GDM Guideline for further information^{68,74,75}.

Thyroid function test

Overt hyper and hypothyroidism are both associated with stillbirth⁷⁶. However the effect on stillbirth of subclinical hypothyroidism or a positive thyroid antibody test in pregnancy is not clear^{77,78}. Due to this very low risk of stillbirth, routine screening of thyroid function in a clinically euthyroid woman after stillbirth is of limited value⁷⁹.

Liver function tests and bile acids

Abnormalities in liver function tests are markers for viral hepatitis, acute fatty liver of pregnancy, HELLP syndrome and obstetric cholestasis (OC)^{80,81}. Obstetric cholestasis (OC) is a pregnancy-specific liver disease, characterised by maternal pruritus and raised serum bile acids. Risk factors for OC include ethnicity, history of previous liver and/or gallbladder disease including hepatitis B and C, prior OC and multiple pregnancy. A large prospective study of has confirmed the association between severe OC and adverse perinatal outcomes including⁸². The association was maintained despite bile acid testing being non-fasting. Liver function and (non-fasting) bile acid testing is therefore recommended following the diagnosis of fetal death if there is a maternal history of pruritus.

Drug screen

Illicit drug use including amphetamine, methamphetamine, cocaine, pethidine, meperidine, hydrocodone, and tetrahydrocannabinolic acid may contribute to a range of adverse pregnancy outcomes, and use of these substances has been associated with a 2-3 fold increased risk of stillbirth⁸³. While screening for illicit substance use is not recommended as a routine investigation following stillbirth, testing should be considered where indicated on the basis of maternal history.

5.8 Alternative investigations: When permission for full autopsy is not obtained

Parents should be informed about the possibility of missing an important finding when a full autopsy is not undertaken. If permission for a full autopsy is not obtained, an external examination, X-ray (babygram) and clinical photos (as described above) are important investigations to perform^{6,84}.

Where available, Magnetic Resonance Imaging (MRI) should be offered to parents who decline an autopsy⁸⁵. MRI may be diagnostic in some cases (e.g. where intracranial abnormalities are detected)⁸⁵⁻⁸⁷. Clinicians should however explain to parents that a full autopsy remains the gold standard, as MRI does not supply tissue samples and therefore important information may be

missed. Other alternatives to a full post-mortem examination including post-mortem needle biopsy; laparoscopic autopsy, and small incision access for focussed investigation of suspected abnormalities.

Please refer to Section 4 Autopsy examination for further details on alternate investigations to autopsy.

5.9 Storage of plasma and amniotic fluid

Unexplained fetal death is currently the subject of extensive research. Storage of placental and fetal DNA, blood and amniotic fluid allows for future testing for other potential factors that are currently not identified. Even if it is not initially possible to provide an explanation as to the cause of death, parents and siblings may benefit from future research findings if material is stored appropriately. Any storage of human samples requires informed consent to be obtained.

The Stillbirth Centre of Research Excellence in Stillbirth is developing a national collaboration in placental sample storage for research purposes.

5.10 References

1. Flenady V, Wojcieszek AM, Middleton P, Ellwood D, Erwich JJ, Coory M, for the Lancet Ending Preventable Stillbirths series study group. Stillbirths: Recall to action in high-income countries. *The Lancet* 2016; **387**(10019): 691-702.
2. Flenady V. Epidemiology of fetal and neonatal death. In: Khong TY, Malcomson RDG, eds. *Keeling's Fetal and Neonatal Pathology*. 5th ed: Springer International Publishing; 2015.
3. Corabian P, Scott A. *Protocols for stillbirth investigation*. Edmonton, Alberta: Alberta Heritage Foundation for Medical Research 2005.
4. Wojcieszek AM, Shepherd E, Middleton P, et al. Interventions for investigating and identifying the causes of stillbirth. *Cochrane Database of Systematic Reviews*. Issue 1. Art. No.: CD012504. DOI: 10.1002/14651858.CD012504 2017.
5. Michalski ST, Porter J, Pauli RM. Costs and consequences of comprehensive stillbirth assessment. *Am J Obstet Gynecol* 2002; **186**(5): 1027-34.
6. Lim TL, Tan KH, Tee CS, Yeo GS. Investigating stillbirths using a simplified obstetric events-based protocol. *Singapore Med J* 2005; **46**(2): 63-8.
7. Korteweg FJ, Erwich JJHM, Timmer A, et al. Evaluation of 1025 fetal deaths: proposed diagnostic workup. *American Journal of Obstetrics and Gynecology* 2012; **206**(1): 53.e1-.e12.
8. Silver RM, Varner MW, Reddy U, et al. Work-up of stillbirth: a review of the evidence. *American Journal of Obstetrics and Gynecology* 2007; **196**(5): 433-44.
9. Smith A, Bannatyne P, Russell P, Ellwood D, den Dulk G. Cytogenetic studies in perinatal death. *Aust NZ J Obstet Gynaecol* 1990; **30**(3): 206-10.
10. O'Leary BD, Walsh CA, Fitzgerald JM, Downey P, McAuliffe FM. The contribution of massive fetomaternal hemorrhage to antepartum stillbirth: a 25-year cross-sectional study. *Acta Obstet Gynecol Scand* 2015; **94**(12): 1354-8.
11. Stroustrup A, Plafkin C, Tran TA, Savitz DA. Demographic and Behavioral Predictors of Severe Fetomaternal Hemorrhage: A Case-Control Study. *Neonatology* 2016; **109**(4): 248-54.
12. de Almeida V, Bowman JM. Massive fetomaternal hemorrhage: Manitoba experience. *Obstet Gynecol* 1994; **83**(3): 323-8.
13. Laube DW, Schauburger CW. Fetomaternal bleeding as a cause for "unexplained" fetal death. *Obstet Gynecol* 1982; **60**(5): 649-51.
14. Froen JF. *Sudden intrauterine unexplained death*. Oslo: Unipub AS, 2002.
15. NSW Health Department. *Guidelines for investigation of a stillbirth*. Sydney, 1997.
16. Nursing and Midwifery Sub-group SZCSN. *Antepartum haemorrhage: Southern Zone Maternity Procedural Guidelines*. 2003. (accessed).
17. Nijkamp JW, Sebire NJ, Bouman K, Korteweg FJ, Erwich JJHM, Gordijn SJ. Perinatal death investigations: What is current practice? *Seminars in Fetal and Neonatal Medicine* 2017; **22**(3): 167-75.
18. Silver RM, Heuser CC. Stillbirth workup and delivery management. *Clinical Obstetrics And Gynecology* 2010; **53**(3): 681-90.
19. Emery CL, Morway LF, Chung-Park M, Wyatt-Ashmead J, Sawady J, Beddow TD. The Kleihauer-Betke test. Clinical utility, indication, and correlation in patients with placental abruption and cocaine use. *Arch Pathol Lab Med* 1995; **119**(11): 1032-7.
20. Carey JC. Diagnostic evaluation of the stillborn infant. *Clin Obstet Gynecol* 1987; **30**(2): 342-51.
21. Curry CJR, Honore LH. A protocol for the investigation of pregnancy loss. *Clinics in Perinatology* 1990; **17**(3): 723-42.
22. Kean L. Intra-uterine fetal death. *Current Obstetrics & Gynaecology* 2003; **13**(6): 329-35.
23. Manitoba CoPaSo. *Investigation of Stillbirths*. Manitoba, 1998.

24. Department of Human Services South Australia. Maternal, Perinatal and Infant Mortality in South Australia 2002. Including South Australian Protocol for investigation of stillbirths. South Australia: Department of Human Services, 2002.
25. British Columbia Reproductive Care Program. Investigation and assessment of stillbirths. British Columbia, 1999.
26. Queensland Maternal and Perinatal Quality Council. Maternal and perinatal mortality audit: Guidelines for maternity hospitals. Queensland: Queensland Government, Queensland Health, 2003.
27. NSW Kids and Families. Stillbirth - Management and Investigation. Sydney: NSW Health Department; 2007.
28. Corabian P, Scott A. Protocols For Stillbirth Investigation. Wisconsin: Alberta Heritage Foundation for Medical Research, 2005.
29. Wisconsin Stillbirth Service Program. Guide to etiologic evaluation of the stillborn infant: The WiSSP Protocol. 2004. <http://www2.marshfieldclinic.org/wissp/guidetoe.htm>.
30. Pacheco MC, Reed RC. Pathologist effort in the performance of fetal, perinatal, and pediatric autopsies: A survey of practice. *Arch Pathol Lab Med* 2017; **141**(2): 209-14.
31. Korteweg FJ, Bouman K, Erwich JJHM, et al. Cytogenetic analysis after evaluation of 750 fetal deaths: proposal for diagnostic workup. *Obstetrics & Gynecology* 2008; **111**(4): 865-74.
32. Reddy UM, Page GP, Saade GR, et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. *New England Journal of Medicine* 2012; **367**(23): 2185-93.
33. Rosenfeld JA, Tucker ME, Escobar LF, et al. Diagnostic utility of microarray testing in pregnancy loss. *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology* 2015; **46**(4): 478-86.
34. Armes JE, Williams M, Price G, et al. Application of whole genome sequencing technology in the investigation of genetic causes of fetal, perinatal, and early infant death. *Pediatr Dev Pathol* 2017: 1093526617715528.
35. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. *The Lancet Infectious Diseases*; **17**(6): e177-e88.
36. Griffiths PD, Baboonian C. A prospective study of primary cytomegalovirus infection during pregnancy: final report. *Br J Obstet Gynaecol* 1984; **91**(4): 307-15.
37. Iwasenko JM, Howard J, Arbuckle S, et al. Human Cytomegalovirus Infection Is Detected Frequently in Stillbirths and Is Associated With Fetal Thrombotic Vasculopathy. *Journal of Infectious Diseases* 2011; **203**(11): 1526-33.
38. Mostoufi-zadeh M, Driscoll SG, Bianco SA, Kundsinn RB. Placental evidence of cytomegalovirus infection of the fetus and neonate. *Arch Pathol Lab Med* 1984; **108**(5): 403-6.
39. Yinon Y, Chitayat D, Blaser S, et al. Fetal cardiac tumors: a single-center experience of 40 cases. *Prenat Diagn* 2010; **30**(10): 941-9.
40. Goldenberg RL, Thompson C. The infectious origins of stillbirth. *Am J Obstet Gynecol* 2003; **189**(3): 861-73.
41. Skjoldbrand-Sparre L, Tolfvenstam T, Papadogiannakis N, Wahren B, Broliden K, Nyman M. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. *BJOG* 2000; **107**(4): 476-80.
42. Wright C, Hinchliffe SA, Taylor C. Fetal pathology in intrauterine death due to parvovirus B19 infection. *BJOG: An International Journal of Obstetrics & Gynaecology* 1996; **103**(2): 133-6.
43. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. *BMJ* 1990; **300**(6733): 1166-70.
44. Crane J. Parvovirus B19 infection in pregnancy. *J Obstet Gynaecol Can* 2002; **24**(9): 727-43; quiz 44-6.

45. Harger JH, Adler SP, Koch WC, Harger GF. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. *Obstet Gynecol* 1998; **91**(3): 413-20.
46. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. *Br J Obstet Gynaecol* 1998; **105**(2): 174-8.
47. Rodis JF, Quinn DL, Gary GW, Jr., et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. *Am J Obstet Gynecol* 1990; **163**(4 Pt 1): 1168-71.
48. Beckwith JB. The value of the pediatric postmortem examination. *Pediatr Clin North Am* 1989; **36**(1): 29-36.
49. Benirschke K, Robb JA. Infectious causes of fetal death. *Clin Obstet Gynecol* 1987; **30**(2): 284-94.
50. Bukowski R, Carpenter M, Conway D, et al. Causes of death among stillbirths. *Obstetrical & Gynecological Survey* 2012; **67**(4): 223-5.
51. Arnesen L, Martinez G, Mainero L, Serruya S, Duran P. Gestational syphilis and stillbirth in Latin America and the Caribbean. *Int J Gynaecol Obstet* 2015; **128**(3): 241-5.
52. Qin J, Yang T, Xiao S, Tan H, Feng T, Fu H. Reported estimates of adverse pregnancy outcomes among women with and without syphilis: a systematic review and meta-analysis. *PLoS one* 2014; **9**(7): e102203.
53. Moise K. Hemolytic disease of the fetus and newborn. In: Creasy R, Resnik R, eds. *Maternal-Fetal Medicine: Principles and Practice*. Fifth ed. Philadelphia: Saunders; 2004: 537-61.
54. Korteweg FJ, Erwich JJHM, Folkeringa N, et al. Prevalence of parental thrombophilic defects after fetal death and relation to cause. *Obstetrics & Gynecology* 2010; **116**(2, Part 1): 355-64.
55. Silver RM, Saade GR, Thorsten V, et al. Factor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase mutations and stillbirth: the Stillbirth Collaborative Research Network. *Am J Obstet Gynecol* 2016.
56. Simcox LE, Ormsher L, Tower C, Greer IA. Thrombophilia and pregnancy complications. *International journal of molecular sciences* 2015; **16**(12): 28418-28.
57. Nijkamp JW, Sebire NJ, Bouman K, Korteweg FJ, Erwich JJHM, Gordijn SJ. Perinatal death investigations: What is current practice? *Seminars in Fetal and Neonatal Medicine*.
58. Rezk M, Dawood R, Badr H. Maternal and fetal outcome in women with antiphospholipid syndrome: a three-year observational study. *J Matern Fetal Neonatal Med* 2016: 1-5.
59. Alberman E, Botting B, Blatchley N, Twidell A. A new hierarchical classification of causes of infant deaths in England and Wales. *Arch Dis Child* 1994; **70**.
60. Simchen MJ, Ofir K, Moran O, Kedem A, Sivan E, Schiff E. Thrombophilic risk factors for placental stillbirth. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2010; **153**(2): 160-4.
61. Hiltunen LM, Laivuori H, Rautanen A, et al. Factor V Leiden as risk factor for unexplained stillbirth – a population-based nested case-control study. *Thrombosis Research* 2010; **125**(6): 505-10.
62. Silver RM, Parker CB, Reddy UM, et al. Antiphospholipid antibodies in stillbirth. *Obstet Gynecol* 2013; **122**(3): 641-57.
63. Monari F, Alberico S, Avagliano L, et al. Relation between maternal thrombophilia and stillbirth according to causes/associated conditions of death. *Early human development* 2012; **88**(4): 251-4.
64. Helgadottir LB, Skjeldestad FE, Jacobsen AF, Sandset PM, Jacobsen EM. The association of inherited thrombophilia and intrauterine fetal death: A case-control study. *Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis* 2011; **22**(8): 651-6.
65. Liatsikos SA, Tsikouras P, Manav B, Csorba R, von Tempelhoff GF, Galazios G. Inherited thrombophilia and reproductive disorders. *Journal of the Turkish German Gynecological Association* 2016; **17**(1): 45-50.
66. Cundy T, Gamble G, Townend K, Henley PG, MacPherson P, Roberts AB. Perinatal mortality in Type 2 diabetes mellitus. *Diabet Med* 2000; **17**(1): 33-9.

67. Flenady V, Koopmans L, Middleton P, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. *The Lancet* 2011; **377**(9774): 1331-40.
68. Hoffman L, Nolan C, Wilson JD, Oats JJ, Simmons D. Gestational diabetes mellitus--management guidelines. The Australasian Diabetes in Pregnancy Society. *Med J Aust* 1998; **169**(2): 93-7.
69. Draper ES KJ, Kenyon S. (Eds.) on behalf of MBRRACE-UK. MBRRACE-UK Perinatal Confidential Enquiry: Term, singleton, normally formed, antepartum stillbirth Leicester: The Infant Mortality and Morbidity Studies, Department of Health Sciences, University of Leicester, 2015.
70. Rowan J, Allen H, Budden A, et al. New Zealand National GDM Guidelines: an alternative view of some good practice points. *Aust NZ J Obstet Gynaecol* 2015; **55**(1): 17-20.
71. Parfitt VJ, Clark JD, Turner GM, Hartog M. Use of fructosamine and glycated haemoglobin to verify self blood glucose monitoring data in diabetic pregnancy. *Diabetic Medicine* 1993; **10**(2): 162-6.
72. Khalafallah A, Phuah E, Al-Barazan AM, et al. Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus. *BMJ Open* 2016; **6**(4): e011059.
73. Soumya S, Rohilla M, Chopra S, et al. HbA1c: A Useful Screening Test for Gestational Diabetes Mellitus. *Diabetes technology & therapeutics* 2015; **17**(12): 899-904.
74. Oats JJN, McIntyre HD. Revision of guidelines for the management of gestational diabetes mellitus. *Medical Journal of Australia* 2004; **181**(6): 342.
75. Nankervis A, McIntyre H, Moses R, et al. Australasian Diabetes In Pregnancy Society (ADIPS) Consensus guidelines for the testing and diagnosis of gestational diabetes mellitus in Australia 2013. <http://adips.org/downloads/ADIPSConsensusGuidelinesGDM-03.05.13VersionACCEPTEDFINAL.pdf> (accessed).
76. Andersen SL, Olsen J, Wu CS, Laurberg P. Spontaneous abortion, stillbirth and hyperthyroidism: a danish population-based study. *European thyroid journal* 2014; **3**(3): 164-72.
77. Feki M, Omar S, Menif O, et al. Thyroid disorders in pregnancy: frequency and association with selected diseases and obstetrical complications in Tunisian women. *Clin Biochem* 2008; **41**(12): 927-31.
78. Nazarpour S, Ramezani Tehrani F, Simbar M, Azizi F. Thyroid dysfunction and pregnancy outcomes. *Iranian journal of reproductive medicine* 2015; **13**(7): 387-96.
79. Nijkamp JW, Korteweg FJ, Groen H, et al. Thyroid function testing in women who had a stillbirth. *Clinical endocrinology* 2015.
80. McDonald JA. Cholestasis of pregnancy. *J Gastroenterol Hepatol* 1999; **14**(6): 515-8.
81. Pathak B, Sheibani L, Lee RH. Cholestasis of pregnancy. *Obstetrics and gynecology clinics of North America* 2010; **37**(2): 269-82.
82. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. *Hepatology (Baltimore, Md)* 2014; **59**(4): 1482-91.
83. Varner MW, Silver RM, Hogue CJR, et al. Association between stillbirth and illicit drug use and smoking during pregnancy. *Obstetrics and gynecology* 2014; **123**(1): 113-25.
84. Arthurs OJ, Sebire NJ. Perinatal Imaging. *Keeling's Fetal and Neonatal Pathology*: Springer; 2015: 123-40.
85. Arthurs OJ, Taylor AM, Sebire NJ. Indications, advantages and limitations of perinatal postmortem imaging in clinical practice. *Pediatric Radiology* 2015; **45**(4): 491-500.
86. Thayyil S, Sebire NJ, Chitty LS, et al. Post-mortem MRI versus conventional autopsy in fetuses and children: a prospective validation study. *The Lancet* 2013; **382**(9888): 223-33.
87. Vullo A, Panebianco V, Cannavale G, et al. Post-mortem magnetic resonance foetal imaging: a study of morphological correlation with conventional autopsy and histopathological findings. *La Radiologia medica* 2016; **121**(11): 847-56.

5.11 Section authors

Glenn Gardener, Vicki Flenady, Aleena M Wojcieszek, Lesley McCowan, Antonia Shand, Adrienne Gordon, Dell Horey, Kassam Mahomed, David Ellwood, Jeremy Oats, Jane Dahlstrom, Jane Zuccullo, Natasha Donnelly, Yee Khong, Hanna Reinebrant.

5.12 Acknowledgements

Lynn Sinclair, in her role as chair of the PSANZ Policy Committee, for facilitating this update. Eszter Katona and Sarah Henry for assisting with coordination and compilation of this section and Elizabeth Flenady for assisting with reference management. We thank Bob Silver for advice on this section of the guidelines.

5.13 Appendices

Appendix A – Stillbirth investigations algorithm

Appendix B – Estimation of severity of foeto-maternal haemorrhage

Appendix C – Placental examination; Accoucheur flow chart

Appendix D – Clinical examination of baby checklist

Appendix E – Australian perinatal mortality audit tool

Appendix F – New Zealand Rapid reporting form for a perinatal death - baby

Appendix G – New Zealand Rapid reporting form for a perinatal death - mother

Appendix H – Instructions on taking clinical photographs

Appendix I – Autopsy clinical summary form

Appendix J – Perinatal mortality classifications: Quick reference sheet

Appendix K – WHO mortality audit meeting code of practice declaration

Appendix L – Birthweight percentiles

Appendix M – Infant autopsy consent brochure

Appendix N – Information for health professionals seeking consent

Appendix O – RCPATH Guidelines for Autopsy Investigation of Fetal and Perinatal Death

Appendix P – Placental histopathology reporting form

Appendix Q – Suspected genetic metabolic disorders

Appendix R – Screening for genetic metabolic disorders

Appendix S – Components of the genetic autopsy for investigations of metabolic disorders

Appendix T – Australian and New Zealand definitions of perinatal mortality